Searchable abstracts of presentations at key conferences in endocrinology

ea0032p598 | Female reproduction | ECE2013

Association of thyroid autoimmunity and thyroid dysfunction with obstetric antiphospholipid syndrome

Jelic Svetlana , Stojanovich Ljudmila , Marisavljevic Dragomir

Background: The association of antiphospholipid syndrome (APS) with various endocrine disorders is already known. However, data on the influence of thyroid autoantibodies and/or disorders of thyroid function on the expression of classical APS manifestations are rather limited.Objectives: The aim of this investigation was to evaluate the impact of thyroid autoimmunity and dysfunction on frequency of recurrent miscarriages in patients with primary antiphos...

ea0041s15.2 | In the rhythm of EYES: Let's dance! | ECE2016

Jive up your judgement! Density is not the destiny – the lessons from vertebral morphometry and bone turnover in acromegaly

Stojanovic Marko

Skeleton is an emerging target for systemic complications in acromegaly. The GH/IGF-1 excess is believed to cause an increased bone turnover and negative calcium balance. Observations on bone mineral density (BMD) in acromegalic patients are inconsistent, possibly in relation to skeletal site and method of BMD measurement or gonadal status. Reports on skeletal fragility are also conflicting but it is predominantly believed that an increase of vertebral fractures (VFs) risk is ...

ea0063ep121 | Pituitary and Neuroendocrinology | ECE2019

Delayed diagnosis of acromegaly: a two-year journey

Bitar Asma Amalia , Stojanovic Nemanja , Mlawa Gideon

Aims: To present the case of a 69-year-old female patient who was diagnosed with acromegaly two years following the initial onset of facial and acral symptoms, having already developed colonic hyperplastic polyps, one of the complications associated with acromegaly, one year prior to diagnosis.Material: Case report and literature review.Method: Acromegaly was diagnosed based on clinical suspicion, raised IGF-1 level, absence of GH ...

ea0056p636 | Clinical case reports - Thyroid/Others | ECE2018

Primary haemoglobinopathies as a cause of secondary endocrinopathies

Subramaniam Yuvanaa , Mlawa Gideon , Stojanovic Nemanja

Background: Haemoglobinopathies are inherited disorders of haemoglobin that predispose to endocrinopathies. The common ones include growth delay, hypogonadism and subsequent osteopaenia. Less commonly seen are diabetes mellitus, thyroid and adrenal disorders. Aetiology is multifactorial and includes tissue hypoxia, chronic anaemia, iron overload, high energy demand, genetic influence and malnourishment. We present three case reports which illustrate the endocrinopathies amongs...

ea0090ep22 | Adrenal and Cardiovascular Endocrinology | ECE2023

Clinical presentation and cardivascular events in primary hiperaldosteronism

Vujacic Natasa , Ciric Jasmina , Zivaljevic Vladan , Slijepcevic Nikola , Stojanovic Milos

Introduction: Primary aldosteronism (PA) is characterized by symptoms caused by hypertension and hypokalemia. Some cardiovascular events are found to be more common due to the additional negative effect of aldosterone. The aim of the study was to analyse clinical characteristics of the PA due to adenoma (APA) and to compare the frequency of cardiovascular diseases with those found in adrenal Cushing’ syndrome (CS) and adrenal adenoma associated with essential hypertension...

ea0063p629 | Interdisciplinary Endocrinology 1 | ECE2019

Gender affirming therapy in Female to Male individuals – lipid profile alterations

Miletic Marija , Gajic Milina Tancic , Stojanovic Milos , Vujovic Svetlana

Background: Individuals with gender incongruence receive gender affirming therapy which is fundamental to sex reassignment. Cross sex hormone treatment both improves and impairs several surrogate markers of cardiovascular risk. In the aging population of transsexual persons, we are called to address clinical endpoints of the long-term gender affirming hormone therapy.Aim: Aim was to assess changes in the fasting serum lipid profile during gender affirmin...

ea0063p753 | Thyroid 2 | ECE2019

Falsely high serum calcitonin levels

Stojkovic Mirjana , Beleslin Biljana , Ciric Jasmina , Stojanovic Milos , Zarkovic Milos

Calcitonin is a polypeptide hormone synthesized and secreted by the parafollicular cells of the thyroid gland, and has been considered as a good marker for medullary thyroid carcinoma. But several physiologic and pathologic conditions other than medullary thyroid carcinoma have been associated with increased levels of calcitonin. A 39-year old woman was admitted to our hospital for further testing due to high calcitonin level (467 ng/L) measured by immunochemiluminometric assa...

ea0049ep892 | Neuroendocrinology | ECE2017

Pituitary stalk lesions - experience of single center

Doknic Mirjana , Pekic Sandra , Miljic Dragana , Stojanovic Marko , Petakov Milan

Introduction: Lesions of the pituitary stalk (PSL) are a challenging diagnostic problem for clinicians. Because of the critical location and role of the pituitary stalk, mass lesions in this area are not often biopsied, and the diagnosis may be based on clinical evaluation and imaging. Due to biopsy risk, about 40% PSL diagnosis are ‘probable’ or ‘unknown’.The main clinical symptoms of PSL are visual field defect, DI and hypopituitarism.<p class="abstex...

ea0044ep46 | (1) | SFEBES2016

Management of Thyrotoxicosis with Chronic Neutropenia; Case Report

Pasha Nida , Hodson Kathryn , Vidarthyi M , Stojanovic Nemanja , Nkonge Frederick

The new patient with Thyrotoxicosis and neutropenia is not uncommon and requires focussed deliberations on avoidance of iatrogenic neutropenic injury and raises a clinical dilemma when treating patients with pre-existing neutropenia.There is a paucity of published experience on the safety of Carbimazole and Propylthiouracil in defined neutropenic Thyrotoxic patient’s preparation for definitive ablative RAI therapy or thyroidectomy.<p class="abst...

ea0044ep49 | (1) | SFEBES2016

A case of Euglycaemic Diabetic Ketoacidosis in a patient treated with Canagliflozin

Hodson Katherine , Pasha Nida , Casey Edel , Yakandawala Gangani , Stojanovic Nemanja

Canagliflozin is an oral hypoglycemic agent from the novel class of Sodium Glucose co-Transporter 2 (SGLT2) inhibitors, used in the treatment of patients with Type 2 Diabetes Mellitus (T2DM). Although effective in treatment of hyperglycemia, these medications have been linked to development of diabetic ketoacidosis (DKA) in patients with T2DM. We describe the case of a patient with T2DM, who presented with severe metabolic acidosis while taking Canagliflozin.<p class="abst...